Articles: function.
-
Critical care medicine · Mar 2014
FTY720 (S)-Phosphonate Preserves Sphingosine 1-Phosphate Receptor 1 Expression and Exhibits Superior Barrier Protection to FTY720 in Acute Lung Injury.
Effective therapies are needed to reverse the increased vascular permeability that characterizes acute inflammatory diseases such as acute lung injury. FTY720 is a pharmaceutical analog of the potent barrier-enhancing phospholipid, sphingosine 1-phosphate. Because both FTY720 and sphingosine 1-phosphate have properties that may limit their usefulness in patients with acute lung injury, alternative compounds are needed for therapeutic use. The objective of this study is to characterize the effects of FTY720 (S)-phosphonate, a novel analog of FTY720-phosphate, on variables of pulmonary vascular permeability in vitro and alveolar-capillary permeability in vivo. ⋯ FTY720 (S)-phosphonate is a promising barrier-promoting agent that effectively maintains sphingosine 1-phosphate receptor 1 levels and improves outcomes in the bleomycin model of acute lung injury.
-
Pleural Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Patients coming for preoperative evaluation are often diagnosed for first time with underlying diseases that go unnoticed unless patients present for evaluation. One such example is hypoxia. We present 74 year-old male with no significant past medical history coming for preoperative evaluation for cataract surgery and was hypoxic. With careful assessment of history and physical exam along with imaging revealed asbestosis, thus highlighting importance of occupational exposure. ⋯ The following authors have nothing to disclose: Meenal Malviya, Asad Omar, Navneet Kumar, Muhammad EhteshamNo Product/Research Disclosure Information.
-
BronchiectasisSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: To assess the effectiveness of inhaled colistin in elderly patients with bronchiectasis and chronic bronchial PA infection in reducing hospital readmissions ⋯ The following authors have nothing to disclose: Eva Tabernero, Pilar Gil, Ramon Alkiza, Javier Garros, Anibal Hernandez, Juan Luis ArtolaNo Product/Research Disclosure Information.
-
Congenital Disorder Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Primary ciliary dyskinesia(PCD) is a well-known congenital disorder manifesting in infancy to childhood in 70-80% cases, with the rest being diagnosed in their second decade. The ciliary dysfunction affects the upper and lower respiratory apparatus leading to recurrent sinus infections, pneumonias and irreversible processes including bronchiectasis usually before reaching adulthood. ⋯ The following authors have nothing to disclose: Prashanth Thalanayar, Fernando HolguinNo Product/Research Disclosure Information.
-
Critical CareSESSION TYPE: Slide PresentationPRESENTED ON: Saturday, March 22, 2014 at 04:15 PM - 05:15 PMPURPOSE: Non invasive ventilation (NIV) is a standardized treatment that has proven beneficial effects in different respiratory and cardiologic diseases. The increasing development of NIV has enabled chest physicians to assist more complex patients and stimulate the setting-up of specials units (Respiratory High-Dependency Care Units [RHDCU]). These units are specialized in severe respiratory patients who need NIV and monitoring. The aim of this study was to evaluate the impact of a RHDCU in non-invasive ventilated patients. ⋯ The following authors have nothing to disclose: Alejandro Peralta, Lucia Gimeno, Cristina Oliver, Alicia Binimelis, Belen Nuñez, Miguel Carrera, Monica de la Peña, Ernest SalaNo Product/Research Disclosure Information.